BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call
read more...
Jun 05, 2017
BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting
read more...
May 17, 2017
BeiGene to Present at the 2017 UBS Global Healthcare Conference
read more...
May 10, 2017
BeiGene Reports First Quarter 2017 Financial Results
read more...
Apr 21, 2017
BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
read more...
Apr 21, 2017
BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
read more...
Apr 02, 2017
BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
read more...
Mar 22, 2017
BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results
read more...
Mar 09, 2017
BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL
read more...
Mar 07, 2017
BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility
read more...
Mar 02, 2017
BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111
read more...
Mar 02, 2017
BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
read more...
Feb 27, 2017
BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference
read more...
Feb 08, 2017
BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference
read more...
Jan 25, 2017
BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia
read more...
Dec 30, 2016
BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317
read more...
Dec 21, 2016
BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290
read more...
Dec 05, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting
read more...
Dec 05, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting
read more...
Nov 23, 2016
BeiGene Announces Closing of $200 Million Public Offering
read more...
